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General Summary 
Infection with the human immunodeficiency virus (HIV) leads to immunosuppression, mainly 
through depletion of CD4+ T cells.  Anti-retroviral therapy (ART) inhibits virus replication and 
thereby promotes recovery of T cell numbers and reconstitution of cellular immunity.  Importantly, 
ART improves control of opportunistic infections, increases quality of life and restores life 
expectancy of HIV-infected individuals [1, 2]. 
 
We assessed how HIV-infected individuals compare to HIV-negative individuals in terms of 
mounting an influenza-vaccine specific humoral and cellular immune response.  We were able to 
show that the influenza-specific IgM- but not the IgG response was absent in HIV-infected 
individuals with low CD4+ T cell counts.  Moreover, expansion of IFN-γ secreting CD4+ T cells 
was impaired.  These findings point out the importance of building B cell memory while 
immunological competence is maintained. 
 
Fingolimod-treated individuals have –similar to HIV-infected untreated individuals– low CD4+ T 
cell counts in their peripheral circulation.  In the second section of the thesis we characterized 
cellular and humoral immune responses to influenza-vaccine in fingolimod-treated patients 
(diagnosed with multiple sclerosis), and in untreated healthy controls.  Intriguingly, vaccine-
triggered T cells accumulated normally in blood of fingolimod-treated individuals, despite reduced 
peripheral T cell counts.  Concentrations of anti-influenza A/B IgM and IgG also increased 
similarly in both groups.  These results indicate that fingolimod-treated individuals can mount 
vaccine-specific adaptive immune responses comparable to healthy controls. 
 
Natural killer cells (NK cells) have the ability to link the innate to the adaptive immune system.  
We determined the Killer-cell immunoglobulin-like receptor (KIR) genotype in two cohorts of 
healthy and one cohort of HIV-infected individuals, and related genotype and influenza-vaccine 
induced adaptive immune response(s).  These experiments uncovered enhanced vaccine-
specific CD4+ T cell-immunity to be induced in HIV-negative but not HIV-positive individuals 
bearing the KIR 2DS1/3DS1 genes. 
 
Following up on our observation that NK cell-receptor gene polymorphisms impact adaptive 
immune responses we lastly tested the hypothesis that NK cells may directly impact the 
interaction between dendritic cells (DCs) and T cells.  Assessing this interaction in vitro we were 
able to demonstrate that LPS-matured DCs, but not immature DCs, have the capacity to induce 
immunosuppressive reactivity in autologous NK cells. 
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General Introduction 
The acquired immunodeficiency syndrome (AIDS) is caused by the human immunodeficiency 
virus (HIV) [3, 4].  Although CD4+ T cells represent the primary target for the virus, other 
lymphocyte populations are affected as well.  Apart from a polyclonal B cell dysfunction, the virus 
induces B cell hyperactivation, which results in a hypergammaglobulinemia.  While evidence that 
HIV can infect B cells in vivo is lacking, it has been shown that HIV interacts directly with B cells 
through CD21.  This association is mediated through complement [5].  The factors causing 
hyperactivity of B cells remain largely unknown.  Studies that focused on that issue indicate that 
the following cytokines/pathway may be involved: Interferon-α (IFN-α) [6], tumor necrosis factor-α 
(TNF-α) [7], IL-6 [8], IL-10 [9], CD40 Ligand (CD40L) [9] and B-cell-activating factor (BAFF) [10].  
In vivo, infection with HIV modifies circulating B cell subpopulations.  Of note, early HIV-specific 
B cell responses are directed against non-neutralizing epitopes of the viral envelope.  Later 
during infection, when B cells secrete neutralizing antibodies, the rapidly diversifying virus is 
already in a winning margin [11]. 
The key feature of a progressing HIV-infection is reflected in the decline of CD4+ T cell counts.  
The CD4+ T cell counts represent an important parameter to monitor the immune status of 
infected patients.  Antiretroviral therapy (ART) is highly efficient in suppressing viral replication 
and leads to recovery of CD4+ T cell counts [12]. 
Infection with influenza remains a threat for immunocompromised patients like HIV-infected 
individuals.  Therefore, the “Center for Disease Control and Prevention (CDC)” recommends 
yearly vaccination against influenza.  
Influenza viruses can be distinguished according to their subtypes of the surface molecules, 
hemagglutinin (HA) and neuraminidase (NA).  HA and NA are highly variable epitopes, able to 
undergo genetic and antigenic variation in order to escape immune response.  Neutralizing 
antibodies can provide immediate protection, whereas the clearance is finally mediated by the 
cellular immune response [13].  Protection can be mediated either by CD8+ T cells or appropriate 
antibodies as various experiments with mice showed. Mice lacking both are not able to survive an 
infection [14].  In line with these findings, mice with severe combined immunodeficiency succumb 
to influenza infections, but can be rescued by injection of a dose containing an HA-specific 
monoclonal antibody [15]. 
Vaccination e.g. with a trivalent inactivated vaccine leads to a protective antibody response which 
peaks 2-3 weeks postvaccination.  The most prominent antibody class after influenza vaccination 
is IgG (particularly IgG1) with lower concentrations of IgM and IgA [16]. Antibodies against 
influenza are predominantly directed against the highly variable HA and NA, whereas epitopes 
recognized from cytotoxic T cells are present on nucleoprotein (NP), or the RNA polymerase 
basic protein 2 (PB2) and polymerase acidic protein (PA). 
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Antibodies directed against HA or NA prevent the entrance and release of the virion, respectively, 
whereas activated CD8+ T cells release cytokines with antiviral activity like IFN-γ or tumour-
necrosis factor (TNF) [13].  
The role played by CD4+ T cells in influenza infection has been neglected for a long period 
because of early findings that mice lacking CD4+ T cells were still able to clear the virus. Even 
the antibody titer seemed to be comparable [17]. 
The important role for CD8+ T cells in fighting influenza infection has been demonstrated during 
infection in mice with deficiency in humoral immunity [18, 19].  However, despite the protective 
role of CD8+ T cells, memory CD8+ T cells generated following vaccination were only mildly 
protective [20, 21]. 
Influenza-specific CD4+ T cells are generated from both, natural infection and vaccination. A very 
recent finding demonstrated that HA-specific CD4+ T cells were able to mediate protection from 
influenza infection when CD4+ T cells were transferred in lymphocyte deficient RAG-mice.  This 
was dependent on IFN-γ production because antibody-mediated neutralization of IFN-γ abrogated 
the protective effect [22]. 
 
In the first section of the thesis we investigated humoral and cellular immune responses after a 
virosome-based vaccination in HIV-infected patients with low and high CD4+ T cell counts and in 
HIV-negative controls. Using a virosome-based vaccine as the source of antigen in the ELISpot 
assays provided an opportunity to further investigate the “helping” role of CD4+ T cells. 
We were also interested in influenza-specific IgG and IgM to further discriminate the “helping” role 
of CD4+ T cells:  When antigen activates B cells as well as T cells, T cells provide “help” for the B 
cells to induce isotype switching and somatic mutation. But B cells can also be activated without 
T cell help. Antigens, which have repetitive structures, e.g. like polysaccharides, or are polyclonal 
B cell activators, can induce B cell responses independent of T cell help [23]. IgM is either 
produced by “natural” B-1 cells or as antigen-induced IgM by conventional (B-2) cells [24]. 
How influenza triggers B cell response is incompletely understood. Rothaeusler et al. could 
identify that follicular B cells rapidly induced extrafollicular foci to produce HA-specific antibodies. 
Interestingly, increased CD4+ T cell help enhanced the magnitude of extrafollicular responses 
[25]. 
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Multiple sclerosis [26] is a relatively common disease for which has been documented that 
autoimmune T cells are directed against antigens in the central nervous system (CNS).  The 
auto-immune inflammation is predominantly mediated by CD4+ T cells, but CD8+ T cells also 
enter the inflamed tissue [27].  The drug FTY720 (fingolimod) is an analog of the sphingosine-1-
phosphate (S1P) and interacts with S1P receptors.  FTY720 has shown clinical and radiological 
efficiency in patients with MS.  FTY720 differentially downregulate S1P1 surface expression in 
T cells, and since T cells migrate out of lymph nodes along a S1P gradient, the drug inhibits T cell 
egress from lymph nodes [28, 29].  As a consequence, naïve T cells and central memory T cells 
remain in the lymph node and CCR7 negative T cells are the abundant T cell population in 
peripheral blood.  In Section 2 of the thesis we investigated how FTY720 treatment impacts the 
immune response to influenza vaccination. 
 
Natural killer cells (NK cells) comprise 5-10% of peripheral blood lymphocytes and belong to the 
first line of defense [30].  NK cells mediate cytotoxic immune responses without prior sensitization 
–hence their name.  On their cell surface, NK cells express activating and inhibiting receptors.  
Killer-cell immunoglobulin-like receptors (KIR) belong to a receptor family of activating and 
inhibiting receptors [31].  Inhibitory KIR signal through an ITIM [32, 33], while activating KIR 
recruit the DAP-12 molecule [34].  In the past years it has been revealed that 15 distinct KIR gene 
loci exist (including two pseudogenes KIR2DP1 and KIR3DP1).  The KIR nomenclature is based 
on the number of extracellular immunoglobulin domains, called 2D or 3D, and the presence of 
either a long (L) or a short (S) intracellular domain (Fig. 1).  Major ligands for KIR are MHC class I 
molecules.  Among these, HLA-C molecules can be subgrouped into class C1 and C2 molecules, 
where MHC class C1 holds an asparagine at position 80 and is a functional ligand for KIR2DL2 
and KIR2DL3, class C2 a lysine at position 80 and acts as ligand for KIR2DL1.  KIR3DL1 and 
KIR3DS1 have specificity for HLA-A and -B alleles with a polymorphic sequence at position 80 to 
83 (HLA-Bw4 epitope) [35, 36].  The ligands of activating KIR remain largely unknown.  Several 
studies have demonstrated that KIR2DS1 and its counterpart KIR2DL1 have ligand specificities 
for C2 group molecules [37].  KIR-genotypes can be grouped into haplotype A with only KIR2DL4 
as activating KIR, and haplotype B which contains at least another activating KIR (KIR2DS1/2/3/5 
or KIR3DS1) [36].  In almost all individuals four framework genes are found, namely KIR2DL4, 
KIR3DL2, KIR3DL3, and KIR3DP1.  The distributions of gene frequencies of the KIR genes in 
various populations are listed in table 1.  
In the past few years a large number of KIR-genotype–disease phenotype association studies 
have been conducted.  A seminal study from Martin et al. indicated that individuals carrying the 
KIR3DS1 allele in conjunction with HLA class I alleles from HLA-Bw4 that encode an isoleucine at 
position 80 (HLA-BW4-80I) have a slowed progression towards AIDS [38].  Several studies have 
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since described that HLA-Bw4 is associated with enhanced protection from HIV-progression [26, 
39].  Apart from HIV, KIR also play a role in various other infections:  Khakoo et al. demonstrated 
that patients that cleared hepatitis C infection carried an increased frequency of the inhibitory 
receptor KIR2DL3 in combination with HLA-CAsn80 [40].  Stern et al. related activating KIR with an 
improved resistance to CMV reactivation in kidney-transplant recipients [41].  Functional studies 
of KIR –on the other hand– are still sparse:  Alter et al. were able to demonstrate how KIR3DS1+ 
NK cells showed cell contact-dependent inhibition of HIV in cells expressing HLA-Bw4-80I [42].  
Ahlenstiel et al. used an in vitro-infection model for influenza-virus and detected that NK cells 
from HLA-C1 homozygous individuals showed a stronger degranulation and cytokine secretion 
upon infection compared to individuals homozygous for HLA-C2 [43].  In Section 3 of this thesis 
we assessed in a prospective genotype-phenotype association study how distinct KIR/HLA 
compound genotypes relate to the development of an adaptive influenza-vaccine induced 
immune response. 
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Figure 1. Killer-cell immunoglobulin-like receptors (KIR) and their ligands. 
 
Modified from Parham et al. Nature Reviews Immmunology. 2003. 
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Dendritic cells (DC) were discovered in 1973 as antigen-presenting cells (APC), and they have 
subsequently been shown to have a powerful ability to initiate immune responses [44-46].  
Activated DCs home from peripheral tissues into the T cell zones of secondary lymphoid 
organs [47].  The DC lifespan is limited, with a half-life ranging between 1.5 and 2.9 days [48].  
Upon activation, mature DCs up-regulate genes that permit initiation of an adaptive immune 
response [49].  On the other hand, DC can promote tolerance by presenting antigens from dying 
cells without co-stimulation of T cells [50].  Of importance, DCs are functional and phenotypically 
diverse [51], and several DC subpopulations exist, including plasmacytoid dendritic cells and 
conventional dendritic cells.  Both conventional DCs and plasmacytoid DCs can be found in the 
thymus, spleen, lymph node and Peyer`s patch, whereas in the skin and liver only conventional 
DCs are present [52].  It is thought that myeloid progenitors in the bone marrow give rise to 
macrophage-DC progenitors, which further differentiate into monocytes and DC progenitors [53]. 
DC progenitors than likely give rise to conventional DCs and plasmacytoid DCs [54].  Due to 
limited numbers of DCs circulating in blood, in vitro generated DCs are often used for human 
studies.  The prevalent method is to generate monocyte-derived DCs (moDCs) by cultivating 
monocytes in the presence of Interleukin-4 (IL-4) and granulocyte-macrophage colony-stimulating 
factor (GM-CSF). 
Innate recognition of a microorganism is mediated via pathogen recognition receptors (PRRs).  
These PRRs comprise Toll-like receptors (TLRs) and NOD-like receptors [55-57].  The 
expression of TLRs varies between the DC types and subtypes. 
The interaction of DCs with NK cells has been a recent focus of considerable research [58].  DC-
derived cytokines such as IL-2, IL-12, IL-15 and IL-18 can prime NK cell function [59, 60].  In 
addition, NK cells can also be activated through direct cell-cell contact.  For example INF-α 
treatment of DCs leads to upregulation of the NKG2D ligands MICA/B and subsequently to 
activation of NK cells [61].  Recent work has convincingly shown that NK cells can influence 
adaptive immune responses [62-66].  One study has, for example, demonstrated that infection of 
NK cell-depleted mice with T. gondii showed impaired CD4+ T cell responses [67].  In Section 4 
of the thesis we investigated whether NK cells may be differentially activated by immature vs. 
mature monocyte-derived DCs. 
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Section 1: Virosomal influenza-vaccine induced immunity in HIV-infected 
individuals with high versus low CD4+ T cell counts; clues towards a 
rational vaccination strategy 
 
Stefanie Fritz, Erik Mossdorf, Bojana Durovic, Gabriela Zenhaeusern, Anna Conen, Ingrid 
Steffen, Manuel Battegay, Reto Nüesch, Christoph Hess. 
Abstract 
In a prospective influenza-vaccination trial we show that HIV-infected individuals with CD4+ T cell 
counts <350/µL were distinct from HIV-infected individuals with >350 CD4+ T cell counts/µL, and 
from HIV-negative individuals, in that an influenza-specific IgM-response was absent and 
expansion of IFNγ-secreting CD4+ T cells was impaired.  By contrast, IgG-responses were 
induced in all study-groups.  These data suggest that establishing broad influenza-specific (IgG) 
B cell memory prior to severe immunodeficiency is important. 
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Introduction 
Antibody affinity maturation, isotype class-switch and B cell memory formation all depend on 
adequate CD4+ T cell help [1, 2].  By contrast, maintenance of established B cell memory needs 
little or no T cell help in order to persist [3, 4].  In HIV-infection T cell help is progressively lost as 
CD4+ T cell counts decline [5].  Seasonal influenza vaccination is advised for HIV-infected 
individuals [6].  Whether, based on specific immunological assessments, subgroups of HIV-
infected individuals should be vaccinated with priority has not been assessed. 
How in HIV-infected individuals virosomal influenza antigen –known to trigger both cellular and 
humoral immunity [7]– is capable of inducing influenza-specific IgM and IgG, and how this 
antibody-production relates to total CD4+ T cell counts and influenza-specific CD4+ T cell 
function is unknown. 
 
 20 
 
Patients and Methods 
In a prospective observational clinical study we characterized vaccine-specific immunity in 24 
HIV-negative, and in 31 HIV-infected individuals.  Study participants were recruited and followed-
up at the University Hospital Basel during the vaccination season 2007/2008.  Inclusion criteria 
were: age >18 years, and in HIV-infected individuals anti-retroviral therapy (ART) since 
>3 months and HIV viral load <200 copies/µL).  Exclusion criteria were: a febrile illness, allergies 
to compounds of the vaccine, any vaccination within 30 days of inclusion and/or during follow-up, 
concomitant or planed medication with steroids/other immunosuppressive drugs, malignant 
disease, and pregnancy.  The study was IRB approved and written informed consent was 
obtained from all study participants. 
All participants were vaccinated with a trivalent virosomal vaccine (Inflexal V, Berna Biotech, 
Basel, Switzerland).  Blood was collected immediately prior to vaccination, and at day 7 (=follow-
up 1 [FU1]), 14 [=FU2] and 28 [=FU3]) post-vaccination.  Influenza-specific IgM and IgG were 
quantified using a commercially available kit (Genzyme Virotech, Ruesselsheim, Germany), 
antibody-quantifications expressed as mean optical density values from duplicate measurements.  
The frequency of CD4+ T cells secreting IFNγ was measured using ELISpot assays as previously 
described [8], using Inflexal (Berna Biotech, Bern, Switzerland) as the source of antigen.  Peak 
post-vaccination frequencies are shown.  Wilcoxon matched paired test was performed to 
compare frequencies of influenza-specific CD4+ T cells and influenza-specific IgG and IgM 
between differing time-points. 
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Results 
 
Table 1. Patient characteristics 
 
 
 
Clinical characteristics of the study population are summarized in Table 1.  In HIV-negative 
individuals median levels of influenza-specific IgM (FU1-3) and IgG (FU2&3) significantly 
increased as compared to pre-vaccination levels (Figure 1A, left and medium panel).  The 
median frequency of vaccine-induced CD4+ T cells also significantly increased, with a rise 
observed in 22/24 (92%) individuals (Figure 1A, right panel).  In HIV-infected participants with 
preserved CD4+ T cell counts (>350/µL of blood) median levels of influenza-specific IgM (FU1-3) 
and IgG (FU1-3) also significantly increased as compared to pre-vaccination levels (Figure 1B, 
left and medium panel).  However, while the median frequency of vaccine-induced CD4+ T cells 
rose significantly, an increase was observed in only 14/22 individuals (64%) (Figure 1B, right 
panel). 
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Figure 1.  Humoral and cellular immune response in HIV-negative and HIV-infected individuals vaccinated 
with virosomal influenza-antigen.  Humoral and cellular immune response in HIV-negative and HIV-infected 
individuals vaccinated with virosomal influenza-antigen.  Levels of influenza-specific IgM (left panel), 
influenza-specific IgG (medium panel), and the frequency of influenza-specific CD4+ T cells (right panel) is 
shown in HIV-negative study participants (A), HIV-infected study participants with >350 CD4+ T cells/µL (B), 
and in HIV-infected study participants with <350 CD4+ T cells/µL (C).  Dots indicate antibody-measurements 
in individual study participants (horizontal bars indicate median levels); pre- and post-vaccination 
frequencies of influenza-specific CD4+ T cells are linked with black lines in case of expanding responses, 
with red lines in case of contracting responses.  FU1-3 = days 7, 14 and 28 post-vaccination.  Dots present 
values from each participant at indicated time points.  *, Values of p < 0.05; ** a p value of < 0.01 and ***, a 
p value of < 0.001 compared with baseline.  
 
 
In contrast to HIV-negative and HIV-infected individuals with preserved CD4+ T cell counts, in 
HIV-infected study participants with <350 CD4+ T cell counts/µL no significant increase in median 
influenza-specific IgM levels was detected at any follow-up time-point, with only 2/9 participants 
responding at all (Figure 1C, left panel).  However, a significant increase in median levels of 
post-vaccination influenza-specific IgG was observed (Figure 1C, medium panel).  No significant 
increase in the median frequency of vaccine-induced CD4+ T cells was detected in the group of 
individuals with low CD4+ T cell counts, with a response induced in only 4/9 individuals (44%) 
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(Figure 1C, right panel).  Of note, time on ART in 'IgM responders' with low CD4+ T cell counts 
tended to be longer, in 'IgM non-responders' with high CD4+ T cell counts shorter than among 
their respective intra-population controls.  No such trend was observed comparing CDC disease 
stage, nadir CD4+ T cell counts and virological suppression (data not shown). 
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Discussion 
The inability of most HIV-infected individuals with low CD4+ T cell counts to produce detectable 
amounts of influenza-specific IgM was unexpected.  A possible explanation for the observed lack 
of IgM-production could be an intrinsic defect of B cells, which has been demonstrated in patients 
with viremia and –although to a much lesser extent– also in patients with undetectable viral load 
[8, 10].  By contrast, vaccine-induced IgG increased in all study groups, including the one with low 
CD4+ T cell counts.  Given the lack of IgM-response in HIV-infected individuals with low CD4+ T 
cell counts, increasing levels of IgG in this study group most likely reflects a memory response.  
This finding is important and provides an immunological rational supporting the recommendation 
of annual influenza vaccinations throughout the course of HIV-infection, permitting the buildup of 
a broad and long-lasting B cell memory when immunological competence is still maintained.  The 
clinical importance of such memory responses has been impressively underscored during the 
recent influenza H1N1 pandemic, where children –presumably due to a lack of sero-protection 
from cross-reactive antibodies induced by previous contact with influenza antigen– were most 
severely affected [11]. 
Limitations of our study are the lack of qualitative assessments of the humoral and the cellular 
vaccine-specific immune response, patient diversity, and the fact that the study was 
underpowered to evaluate clinical endpoints such as protection from influenza infection.  
However, the read-outs used did permit the capture of decreasing vaccine-inducible cellular 
responsiveness, and they uncovered a likely dependency of the vaccine-response on B cell 
memory in advanced HIV infection.  These preliminary data should trigger future research aiming 
at understanding the molecular basis of the observed lack of IgM-production, and they lend 
support to strictly enacting annual influenza-vaccination in all HIV-infected individuals regardless 
of their CD4+ T cell count. 
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Section 2: Antigen-specific adaptive immune responses in fingolimod-
treated MS patients 1 
 
Matthias Mehling, Stefanie Fritz, Patricia Hilbert, Bojana Durovic, Dominik Eichin, Olivier Gasser, 
Jens Kuhle, Thomas Klimkait, Raja Lindberg, Ludwig Kappos, Christoph Hess. 
Abstract 
T cells exit secondary lymphoid organs along a sphingosine1-phosphate (S1P)-gradient and, 
accordingly, are reduced in blood upon fingolimod-mediated S1P-receptor (S1PR)-blockade.  
Serving as a model of adaptive immunity we characterized cellular and humoral immune 
responses to influenza-vaccine in fingolimod-treated patients with multiple sclerosis and in 
untreated healthy controls.  Although the mode of action of fingolimod might predict reduced 
immunity, vaccine-triggered T cells accumulated normally in blood despite efficient S1PR-
blockade.  Concentrations of anti-influenza A/B IgM and IgG also increased similarly in both 
groups.  These results indicate that fingolimod-treated individuals can mount vaccine-specific 
adaptive immune responses comparable to healthy controls. 
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1 As second author of this report that has been published at the Annals of Neurology, Stefanie 
Fritz was involved in collecting samples, performing ELISpot assays, and in analyzing and 
interpretation of data. 
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Introduction 
In multiple sclerosis (MS) lesions lymphocytes mediate inflammation, demyelination, and axonal 
damage [1].  Lymphocytes that express the chemokine receptor CCR7 are able to migrate from 
peripheral tissues –such as the central nervous system (CNS)– to secondary lymphoid organs 
(SLO) such as lymph nodes, whereas cells not expressing CCR7 (CCR7-negative) do not re-
circulate to SLO on a regular basis.  In order to egress from SLO to the peripheral blood 
circulation cells migrate along a sphingosine 1-phosphate (S1P) gradient [2]. 
The oral S1P receptor (S1PR)-agonist fingolimod –which has shown efficacy in the treatment of 
MS [3-5] – blocks this egress, thereby reducing peripheral lymphocyte counts, in a dose-
dependent manner, to 25-40% of baseline values [3, 6-8].  As a consequence, CCR7-negative 
cells represent the major T cell population circulating in the blood of fingolimod-treated patients.  
Despite severe lymphopenia only few infectious complications were observed in fingolimod-
treated patients with MS.  However, a case of fatal disseminated varicella zoster infection and a 
case of herpes simplex virus type 1 encephalitis nonetheless raise concern with regards to the 
immunological competence vis-à-vis viral pathogens in fingolimod-exposed individuals [5, 9] 
So far only animal data are available on the effect of S1PR-blockade on adaptive immune 
responses following viral antigen exposure.  In simian human immunodeficiency virus (SHIV)-
infected rhesus macaques treatment with fingolimod did not result in deviations from the natural 
pattern of viral control [10].  Treatment with fingolimod also had no effect on the disease course 
and T cell exhaustion in mice infected with lymphocytic choriomeningitis virus (LCMV) [11].  In 
contrast, treatment with fingolimod lead to a significant reduction of influenza-antigen specific 
CD8+ T cells in lungs of animals infected with influenza [12]. 
Fundamental in this context, yet never experimentally addressed in humans, is how blocking 
S1PR impacts on the presence of bulk versus recently antigen-activated T cells in the peripheral 
circulation.  Here we sought to define in a prospective observational study the effect of 
fingolimod-mediated S1PR-blockade on the development of antigen-specific immune responses 
in patients with MS. 
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Patients and Methods 
Study subjects and procedures 
We conducted an open-label, observational, prospective study to assess the adaptive immune 
response induced by influenza-vaccine in fingolimod-treated patients with MS and in healthy 
controls (HC).  The trial was conducted during the influenza-vaccination periods 2008/2009 and 
2009/2010.  The institutional review board of Basel approved the study.  After written informed 
consent, blood samples from study subjects were obtained before and 7, 14 and 28 days after 
seasonal influenza-vaccination with Mutagrip® (Sanofi Pasteur SA, Lyon). Inclusion criteria for 
patients were definite relapsing MS, treatment with fingolimod (either 0.5mg/d or 1.25mg/d), and 
age ≥18 and ≤65 years.  Inclusion criteria for healthy controls were absence of chronic disease 
and age ≥18 and ≤65 years.  Exclusion criteria for patients and controls were known 
hypersensitivity to the vaccine under investigation, fever at time of planned vaccination, influenza 
vaccination <180 days before recruitment into the study, treatment with immunoglobulins or 
exogenous blood products within 90 days before recruitment into the study, simultaneous 
medication with steroids or immunomodulators / immunosuppressants other than fingolimod, and 
pregnancy. 
  
Flow cytometry 
T cells were analyzed for expression of CD3, CD4 and CD8 using a CyAn cytometer 
(DakoCytomation, Glostrup, Denmark) according to standard procedures. The following 
antibodies were used: anti-human CD4 phycoerythrin (PE)-cyanin5 (Cy5) (S3.5), anti-human CD8 
PE (MEM-31) and anti-human CD3 FITC (MEM-57).  As isotype controls served IgG2a-FITC 
(713), IgG2a-PE-Cy5 (upc-10), IgG2a-PE (upc-10) (all from Immunotools, Friesoythe, Germany). 
 
Enzyme linked immuno spot assay 
Enzyme linked immuno-spot (ELISpot) was done as described previously [13] with the 
modification that we used with Inflexal® (Berna Biotech, Bern, Switzerland) as source of antigen 
(year adjusted). Enzyme linked immuno-spot (ELISpot): ELISpot plates (MSIPS4510, Millipore 
AG, Volketswil, Switzerland) were coated with 2 µg/mL of anti-interferon gamma (IFN-γ) mAb 1-
D1K (Mabtech, Nacka Strand, Sweden) overnight.  In each well 200.000 peripheral blood 
mononuclear cells (PBMC) were added in R10 (RPMI 1640 containing 10% heat inactivated Fetal 
Bovine Serum [FBS], 50 U/mL penicillin and 50 µg/mL Streptomycin [all from GIBCO™, 
LuBioScience GmbH, Luzern, Switzerland]) (final volume 130 µL/well).  All measurements were 
performed in duplicates.  Inflexal® was used as source of antigen (year adjusted) at a final 
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concentration of 14 µg/mL for each peptide, phytohemagglutinin (PHA) (1.8 µg/mL; REMEL, 
Oxoid AG, Basel, Switzerland) served as a positive control.  Plates were incubated for 16 hours 
at 37°C with 5% CO2, washed with PBS (phosphate-buffered saline) and blocked with PBS 1% 
FBS.  After washing, plates were incubated with 100 µL anti-IFN-γ mAb (1:200) coupled with 
alkaline phosphatase (7-B6-1-ALP, Mabtech) for 2 hours at room temperature.  Spots were 
developed with HistoMark RED phosphatase system (KPL, Gaithersburg, Maryland, USA) and 
counted with the ELISpot Reader System (CSR01, AID GmbH, Strassberg, Germany) using the 
ELISpot 3.5 software (AID GmbH).  50 spot forming cells (SFC)/10e6 PBMC were defined as cut-
off for a positive antigen-specific response.  EBV- and CMV-specific ELISpot responses were 
assessed in the presence or absence of phosphorylated fingolimod, using EBV- or CMV-infected 
cell lysates (Virusys, http://www. virusys.com) at a final concentration of 10 µg/mL as the source 
of antigen. 
 
Virus specific antigen presentation assay 
EBV-specific T cell responses were characterized in the presence or absence of fingolimod as 
described previously [14]:  Bulk PBMC from healthy EBV positive donors were used to generate 
EBV-transformed B cell clones.  1x105 autologous CD3+ T cells were isolated with MACS bead 
technology (Miltenyi Biotec, Bergisch Gladbach, Germany).  T cells were then cultured with 5x104 
paraformaldehyde-fixed EBV-transformed B cells in 96 well plates in LCM-10 medium 
(supplemented with 200 U/mL IL-2 (Roche, Basel, Switzerland) in the presence of 
phosphorylated or unphosphorylated fingolimod (10 ng/mL each). or medium alone.  On day 3 
fresh medium alone or medium containing phosphorylated or unphosphorylated fingolimod 
supplemented with 200 U/mL IL-2 was added.  By day 7 cultures contained no B cells as 
assessed by CD19 staining and FACScan analysis (data not shown). 
 
Anti-influenza A and anti-influenza B enzyme-linked immunosorbent assay 
Concentrations (given as virotech [VE] units/mL) of IgM and IgG anti-influenza A and anti-
influenza B were determined using a quantitative enzyme-linked immunosorbent assay (ELISA) 
according to the manufacturer (Genzyme Virotech, Ruesselsheim, Germany).  As recommended 
by the manufacturer, seroprotection was defined as an anti-influenza A/B IgG-concentration of 
≥10 VE/mL. 
Statistical analyses 
Data were tested for normality with the Shapiro-Wilk test and Levene’s test was used to assess 
the equality of variances.  Mann-Whitney test was performed in case of non-normality and/or 
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differing variance among study-groups.  Data with normal distribution were assessed by paired 
Student’s two-sided t-test.  Values of p<0.05 were considered to be statistically significant. 
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Results 
Characteristics of the study population are summarized in Table 1 (upper part).  Rates of local 
injection site reactions and general tolerability of the vaccine, as monitored by clinical 
assessments and a patient diary, were comparable in fingolimod-treated patients and HC 
(Table 1, lower part).  Flow cytometric analyses revealed a reduction of mean lymphocyte counts 
in fingolimod-treated patients by 64% compared to the lower limit of the reference range (CD4+ 
by 76-83%, CD8+ by 42-63%) (Figure 1A), an observation that is in line with our previous 
findings [6].  The frequency of T cells producing IFN-γ in response to influenza-antigen was 
assessed by ELISpot. 
Before vaccination, frequencies of influenza-specific IFN-γ secreting T cells were comparable in 
fingolimod-treated patients and HC, as was the number of individuals with no detectable 
influenza-specific response.  By day 7 post-vaccination frequencies significantly increased in both 
groups and reached comparable levels (Figure 1B).  Numbers of influenza-specific T cells 
remained increased and comparable until day 14 post-vaccination in both study groups.  By day 
28 post-vaccination frequencies of IFN-γ secreting cells contracted to pre-vaccination levels in 
both groups. 
No individual mounting a very high frequency of influenza-specific cells was contained in the 
fingolimod-group –a finding which, however, did not reach statistical significance.  No statistical 
significant correlation between lymphocyte counts and vaccine-specific immune responses was 
found in HC or fingolimod-treated individuals (data not shown).  To assess whether fingolimod 
alters antigen-specific triggering of circulating virus-specific T cells or their in vitro induction, the 
effect of active (i.e. phosphorylated) fingolimod on ex vivo triggering and on in vitro expansion of 
antigen-specific T cells was assessed.  In presence versus absence of fingolimod (in its active, 
i.e. phosphorylated form) no differences were detected in either experimental system (Figure 1C 
and D). 
To investigate how S1PR-blockade influences antibody responses we quantified in these same 
patients and HC influenza-specific IgM and IgG antibody production by ELISA.  Pre-vaccination 
levels of anti-influenza A and anti-influenza B IgM were comparably low in fingolimod-treated 
patients and HC.  Following vaccination, concentrations of IgM anti-influenza A and anti-
influenza B increased significantly and comparably in both study groups, and remained increased 
at comparable levels until day 28 post vaccination (Figure 2A/B).    
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Table 1 
  
healthy 
controls 
MS 
fingolimod 
  baseline characteristics 
n 18 14 
median age (years) [range]   37 [19-46]  44 [31-60]  
female/male   6/12 8/6 
median disease duration (years) [range]   N.A. 12.3 [3-20]  
median EDSS [range]   N.A. 2.6 [1.0-4.0]  
median therapy duration (months) [range]   N.A. 36 [7-42]  
fingolimod dosage 0.5mg/1.25mg N.A. 6/8  
    
  tolerability of vaccine / 
incidence of influenza-like illness 
injection-site reactions day 0-3 post vaccination 12/18 (66%) 7/14 (50%) 
general symptoms day 0-3 post vaccination 2/18 (11%) 4/14 (29%) 
MS relapses N.A. 0/14 (0%) 
incidence of influenza-like illness 2/18 (11%) 2/14 (14%) 
 
 
Table 1.  Characteristics of the study population (upper part) and tolerability of influenza vaccination and 
incidence of influenza-like illnesses (lower part). 
Abbreviations: fingolimod-treated patients with multiple sclerosis (MS fingolimod), not applicable (N.A.), 
Expanded Disability Status Scale (EDSS) 
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Figure 1.  Lymphocyte counts, cellular immune response after influenza-vaccination in fingolimod-treated 
patients vs. healthy controls, and virus-specific T cell responses in the presence or absence of fingolimod.  
(A) Mean lymphocyte counts in fingolimod-treated patients with MS and in healthy controls (HC) as 
assessed by flow cytometry (± standard error of the mean).  (B) The frequency of influenza-specific cells in 
fingolimod-treated patients with MS (MS fingolim.) and healthy controls (HC) as detected by spot forming 
cells (SFC) in equal amounts of peripheral blood mononuclear cells (PBMC) is shown before (day 0) and at 
day 7, 14 and 28 after influenza vaccination.  (C) Ex vivo assessment of Epstein-Barr virus (EBV)- and 
cytomegalovirus (CMV)-specific CD4+ T cell-dependent IFN-γ production as detected by spot forming cells 
(SFC) in equal amounts of peripheral blood mononuclear cells (PBMC) from HC in the absence (EBV lysate 
medium) or presence of phosphorylated (active) fingolimod (EBV lysate phosphorylated fingolimod).  
(D) Frequencies of EBV-specific T cells before (day 0, CD3+ T cells) and after expansion of IFN-γ secreting 
cells (day 7) by autologous EBV-transformed B cell clones in the absence (medium alone) and presence of 
fingolimod and phosphorylated fingolimod. 
  * indicates p<0.05 
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Figure 2.  Antibody-response after influenza-vaccination in fingolimod-treated patients and in healthy 
controls.  The concentration of IgM anti-influenza A (panel A) and anti-influenza B (panel B) is shown as 
detected before (day 0) and at day 7, 14 and 28 after influenza vaccination in fingolimod-treated patients 
with MS (MS fingolim.) and healthy controls (HC).  The percentage of patients fulfilling IgG sero-protection 
criteria for influenza A (panel C) and influenza B (panel D) is shown before (day 0) and at day 7, 14 and 28 
after influenza vaccination in fingolimod-treated patients with MS (MS fingolim.) and healthy controls (HC).  
The percentage of initially sero-negative patients converting to seroprotection for influenza A (panel E) and 
influenza B (panel F) following vaccination (day 7-28).  ** indicates p<0.001 
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Before vaccination, 71% of the fingolimod-treated patients and 50% of the HC fulfilled the 
predefined sero-protection criteria (IgG ≥10 VE/mL) for influenza A (p=0.41), 71% of the 
fingolimod-treated patients and 44% of the HC for influenza B (p=0.38), indicating previous 
contact with antigen from these viruses in a substantial proportion of study participants 
(Figure 2C/D).  At day 7 after vaccination the proportion of individuals fulfilling sero-protection 
criteria was comparably increased in both fingolimod-treated patients and HC (influenza A: 
p=0.64, influenza B: p=0.53), and remained increased at days 14 and 28 post vaccination in both 
groups (day 14 and 28: influenza A and B: p=1.0). 
The proportion of individuals converting from undetectable to protective antibody levels was also 
similar in fingolimod-treated patients and HC (Figure 2E/F).  Thus, the vaccine-specific 
production of IgM and, more importantly, IgG in fingolimod-treated individuals was not impaired 
when compared to levels in HC. 
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Discussion 
The key observation of this study was that fingolimod-treated patients with MS –despite severe 
peripheral lymphopenia– could mount a vaccine-specific adaptive immune response that is 
comparable to the response observed in healthy controls.  Finding a similar post-vaccination 
frequency of influenza specific peripheral blood T cells in fingolimod-treated patients and HC –in 
spite of fingolimod-mediated lymphopenia– was unexpected.  This observation indicates that in 
humans lymphocyte-egress from SLO is controlled differentially between lymph-node homing T 
cells interacting with cognate antigen, as opposed to T cells screening for –but not interacting 
with– cognate antigen.  Recent animal data are in line with such a model [15]. 
An impaired antibody-response in fingolimod treated individuals is a concern, as the drug directly 
impacts on germinal center reactions and B cell migration [16, 17].  Again, the vaccine-specific 
production of IgM and IgG in fingolimod treated individuals was, however, not detectably impaired 
when compared to levels in healthy controls, a finding in line with some [18], but not all [17] data 
obtained in animal models. 
Our study has limitations, both from an immunological and from a clinical point-of-view.  The 
vaccination model we used does not take into account the complexity brought by an influenza-
infection or any other virus infection, and our study was underpowered to evaluate clinical 
endpoints such as protection from influenza infection.  Likewise, our experiments detecting 
unchanged EBV-specific immune responses in vitro cannot directly be extrapolated to indicate 
intact immune control of other virus infections (e.g. herpes viruses) in fingolimod-treated 
individuals.  However, the data serve as definite proof-of-principle demonstrating that blocking 
S1P-dependent lymphocyte migration in humans does not hinder the appearance of antigen-
activated T cells in the peripheral circulation, nor does it affect the antibody response 
quantitatively.  Clinical conditions with T cell lymphopenia comparable to the one induced by 
fingolimod (HIV-infection, myelotoxic chemotherapy) are associated with a high risk for 
opportunistic infections [19, 20].  Our data indicate that fingolimod-treated patients in principle can 
mount a virus-specific immune response.  It remains unclear, however, to what extent these 
findings in the context of vaccine-responses allow extrapolation to immunological competence 
vis-à-vis infectious pathogens.  The molecular basis of the observed bypass of S1PR-dependent 
SLO-egress by vaccine-triggered T cells in humans remains to be determined.  For clinicians 
these data are informative when weighing the grade of immunosuppression inflicted on 
individuals treated with fingolimod, and they permit a more rational interpretation of infectious 
complications if they occur. 
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Section 3: In absence of HIV-infection KIR 2DS1 and 3DS1 genes are 
associated with enhanced CD4+ T cell-responses to influenza-vaccine 
 
Stefanie Fritz, Erik Mossdorf, Gabriela Zenhaeusern, Matthias Mehling, Bojana Durovic, Patricia 
Hilbert, Anna Conen, Ludwig Kappos, Manuel Battegay, Martin Stern, Reto Nüesch, Christoph 
Hess. 
Abstract 
Here we monitored influenza-specific CD4+ T cell-responses (IFN-γ secretion) before and after 
influenza vaccination and assessed KIR and HLA genotypes in HIV-negative (n=41) and HIV-
infected individuals (n=21) in a prospective clinical trial. 
Day 7 post-vaccination expansion of influenza-specific CD4+ T cells was observed in HIV-
negative and HIV-infected individuals.  Only in HIV-negative study participants expansion of 
influenza-specific CD4+ T cells was maintained two weeks post-vaccination.  Four weeks post-
vaccination contraction was complete in all study-groups.  Compound KIR/HLA genotypes were 
not related to the increase of influenza-specific CD4+ T cells.  However, in HIV-negative study 
participants (exploratory [n=23] and validation [n=18] cohort) a genotype including activating KIR 
2DS1/3DS1 was associated with a larger day 7 post-vaccination increase of influenza-specific 
CD4+ T cells.  This association was not present in HIV-infected individuals. 
This is the first human study that prospectively links KIR-immunogenetics with the magnitude of 
an antigen-specific T cell-response.  In HIV-infection this association was not observed. 
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Introduction 
Killer cell immunoglobulin-like receptors (KIR) represent an important family of innate immune-
receptors that define cellular reactivity via inhibitory and activating signals [1].  KIR are encoded 
by highly polymorphic genes, and the KIR gene complex is polygenic with varying numbers of 
inhibitory and activating receptors [2].  The principal known ligands of KIR are HLA 
molecules [3,4].  In humans, establishing the functional role of activating KIR in mediating anti-
viral effector function has proven difficult, and direct evidence for their implication in viral control is 
lacking [5].  However, genetic association studies have related specific KIR genes and KIR/HLA 
compound genotypes with the clinical outcome after various types of viral infection [6-8]. 
KIR are expressed on natural killer (NK) cells –representing a key cellular component of the 
innate immune system participating in early responses against infected or transformed cells– as 
well as on subsets of T cells [9-11].  Virus-induced down-modulation of ligands for inhibitory 
murine KIR-analogues on infected cells, as well as cognate KIR-mediated recognition of infected 
cells, has been shown to contribute to NK cell mediated protection from infection [12]. 
The importance of NK cells in controlling HIV-replication is suggested by immunogenetic 
association-studies that related a KIR3DS1/HLA Bw4-I80 compound-genotype with slower 
progression to AIDS as compared to cohorts defined by a genotype including only one or none of 
these alleles [13].  In line with these data, KIR3DS1-expressing NK cells better suppress viral 
replication in vitro in the presence of Bw4-I80-positive HIV-infected CD4+ T cells [14].  
Intriguingly, infection with HIV is also associated with significant changes in the phenotype of 
circulating NK cells which –in turn– relates to a progressive loss of NK cell-function [15]. 
In humans, data directly linking the outcome of adaptive immune responses with innate immune 
mechanisms are lacking.  Here we conducted a prospective influenza vaccine trial comparing 
HIV-negative and HIV-infected individuals, permitting us to longitudinally monitor influenza 
vaccine specific CD4+ T cell-responses in individuals with defined KIR and HLA genotypes. 
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Materials and methods 
Study design, inclusion/exclusion criteria, sampling-scheme and primary read-outs 
We conducted a prospective observational study in HIV-negative and chronically HIV-infected 
individuals vaccinated with standard, year-adjusted influenza-vaccine preparations.  Study 
participants were recruited and followed-up at the University Hospital in Basel.  Inclusion criteria 
were: age >18 years, CD4+ T cell counts >350/µL, anti-retroviral therapy (ART) since >3 months 
(as applicable) and HIV viral load <200 copies/mL (as applicable).  Exclusion criteria were: a 
febrile illness, allergies to compounds of the vaccine, any vaccination within 30 days of inclusion 
and/or during follow-up, concomitant or planed medication with steroids/other 
immunosuppressive drugs, malignant disease, and pregnancy.  The study was IRB approved and 
written informed consent was obtained from all study participants.  Blood was collected 
immediately prior to vaccination and at day 7, 14 and 28 post-vaccination.  The study was open to 
recruit 25 HIV-negative and 25 HIV-infected individuals into exploratory and validation cohorts.  
The primary readouts were 'frequency of influenza vaccine-specific CD4+ T cells', quantified at 
each follow-up time-point, and 'KIR genotype'.  The frequency of influenza vaccine-specific CD4+ 
T cells was compared among HIV-negative and HIV-infected study participants sub-grouped 
according to their KIR genotype.  KIR/HLA compound genotypes were included in the analysis as 
applicable.  Genotyping assays were performed blinded for corresponding functional CD4+ T cell 
analyses.  In order to minimize the risk of false positive findings, statistically significant 
differences in the frequency of influenza vaccine-specific CD4+ T cells between subgroups 
required re-confirmation in an independent similar-sized cohort and using an alternative 
vaccination-product (year adjusted).  The exploratory study groups ('07/'08) were vaccinated with 
a trivalent virosomal vaccine (Inflexal V, Berna Biotech, Basel, Switzerland), the validation cohort 
with a trivalent split vaccine (Mutagrip®, Sanofi Pasteur MSD, Baar, Switzerland). 
Isolation of peripheral blood mononuclear cells and T cell-depletion 
Peripheral blood mononuclear cells (PBMC) were prepared by centrifugation through a density 
gradient on Lymphoprep  (Axis-Shield, Oslo, Norway) and were kept in liquid nitrogen until use.  
After thawing, PBMC were depleted from CD4+ or CD8+ T cells, or NK cells as indicated, using 
magnetic-beads according to the manufacturer's protocol (Miltenyi Biotec, Bergisch-Gladbach, 
Germany).  Depletion efficiency was assessed by flow cytometry and was always >97% (data not 
shown). 
ELISpot assay 
ELISpot plates (MSIPS4510, Millipore AG, Volketswil, Switzerland) were coated with 2 µg/mL of 
anti- IFN γ mAb 1-D1K (Mabtech, Nacka Strand, Sweden) overnight.  In each well 200.000 cells 
 42 
in R10 (RPMI 1640 containing 10% heat inactivated Fetal Bovine Serum (FBS), 50 U/mL 
penicillin and 50 µg/mL Streptomycin (all from GIBCO™, LuBioScience GmbH, Luzern, 
Switzerland) were added in duplicates (final volume 130 µL/well).  Inflexal V (Berna Biotech) was 
used as source of antigen (year adjusted) at a final concentration of 14 µg/mL for each peptide, 
Phytohemagglutinin (PHA) (1.8 µg/mL; REMEL, Oxoid AG, Basel, Switzerland) served as a 
positive control.  Plates were incubated for 16 h at 37°C with 5% CO2, washed with PBS 
(phosphate-buffered saline) and blocked with PBS 1% FBS.  After washing, plates were 
incubated with 100 µL anti-IFN-γ mAb (1:200) coupled with alkaline phosphatase (7-B6-1-ALP, 
Mabtech) for 2 hours at room temperature.  Spots were developed with HistoMark RED 
phosphatase system (KPL, Gaithersburg, Maryland, USA) and counted with the ELISpot Reader 
System (CSR01, AID GmbH, Strassberg, Germany) using the ELISpot 3.5 software (AID GmbH). 
Genotyping 
KIR genotypes were determined by multiplex PCR, followed by a reverse sequence-specific 
oligonucleotide method according to the manufacturer's instructions (Onelambda Inc., Canoga 
Park, Ca, USA).  KIR genes analyzed included 2DL1, 2DL2, 2DL3, 2DL5, 3DL1, 2DS1, 2DS2, 
2DS3, 2DS4, 2DS5, and 3DS1.  The framework KIR genes 2DL4, 3DL2, 3DL3, and the 
pseudogenes 2DP1 and 3DP1 were not analyzed.  Presence of KIR2DS1, KIR2DS2 and 
KIR3DS1 was confirmed by SSP PCR according to a published protocol [23].  HLA genes were 
analyzed by high-resolution (four digit) sequence based genotyping (Histogenetics, New York, 
NY, USA). 
Statistical methods 
The KIR genotype was compared in the three cohorts by Pearson’s chi square test.  Mann-
Whitney U test and Wilcoxon’s signed rank tests were performed to compare frequencies of 
influenza specific CD4+ T cells.  Evolution of influenza specific CD4+ T cells over time was 
analyzed by multivariable linear regression including as covariates the baseline influenza specific 
CD4+ T cell-count, presence of KIR2DS1/KIR3DS1 genes, HIV carrier status, and the interaction 
term of KIR2DS1/KIR3DS1 and HIV.  The impact of the compound KIR/HLA genotype was 
assessed by multivariable linear regression including as covariates the presence of a KIR gene, 
its HLA ligand, and the interaction term of KIR and HLA ligand.  Two sided P values <0.05 were 
considered statistically significant. 
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Results 
Characteristics of the study populations 
Twenty-three HIV-negative (median age 34 years [range 22 to 76 years], 43% female) and 21 
HIV-infected study-participants (median age 45 years [range 21 to 65 years], 19% female) were 
recruited into an exploration cohort investigating immune responses of these populations.  
 
 
 
Figure 1. 
(A) Vaccination-induced influenza-specific IFN-γ secretion of bulk and T cell-depleted PBMC.  Depletion of 
CD4+ T cells in PBMC samples reduced the frequency of spot-forming cells to background-level.  By 
contrast, depletion of CD8+ T cells had no effect on the frequency of spot-forming cells.  A representative 
series of experiments is shown, analogous controls were included in all ELISpot assays. 
(B) NK cells do not contribute to influenza-vaccine specific IFN-γ secretion.  A representative experiment is 
shown: Influenza-vaccine was used as the source of antigen, the frequency of IFN-γ secreting cells 
determined by ELISpot analysis.  Comparing IFN-γ secretion in CD56 depleted PBMC and CD56 expressing 
cells indicates that the CD56 negative fraction is the source of IFN-γ.  The increase in SFC in the CD56 
depleted fraction reflects the increased proportion of CD4+ T cells in CD56 depleted PBMC (data not 
shown).  Mean ± SD of triplicates are shown. 
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The trial took place during the vaccination season '07/'08 (Table 1).  A validation cohort of HIV-
negative subjects was vaccinated '08/'09 (n=18, median age 37 years [range 19 to 46 years], 
33% female).  All study participants adhered to the study protocol and sampling was obtained for 
all predefined time points.  In none of the vaccinated individuals significant adverse reactions or 
non-vaccine related clinically relevant problems occurred. 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Frequency of influenza-specific CD4+ T cells before and after vaccination.  Early after vaccination 
(FU 1 = day 7 post-vaccination) the median frequency of IFN-γ secreting CD4+ T cells significantly increased 
in all three cohorts (HIV-negative Cohort 1 [n=23], HIV-infected Cohort [n=21], and HIV-negative Cohort 2 
[n=18]).  Two weeks after vaccination (FU 2) a significant expansion of influenza-specific CD4+ T cells was 
seen only HIV-negative participants.  Four weeks after vaccination influenza-specific CD4+ T cells were 
contracted to pre-vaccination levels in all three cohorts. * p<0.05 ; ** p<0.01 
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Table 1. Characteristics of study populations. 
	
  
    
Patient Characteristics HIV-negative Cohort 1 HIV-infected HIV-negative Cohort 2 
Study Participants (n) 23 21 18 
Age - median (range) 34 (22-76) 45 (21-65) 37 (19-46) 
Male gender - no. (%) 13 (57%) 17 (81%) 12 (67%) 
    
Lymphocyte Counts - Lymphocytes x10^9/L    
Baseline- median (range) >500 545 (364-941) >500 
Day 84 post-vaccination - median (range) >500 520 (371-972) >500 
  
 
 
Viral Loads - Copies/mL      
Baseline  n.a. <200 n.a. 
Day 84 post-vaccination n.a. <200 n.a. 
    
Therapy    
ART (> 3 months) n.a. 100% n.a. 
    
    
Study year 2007/2008 2007/2008 2008/2009 
Vaccine-Type Inflexal® Inflexal® Mutagrip® 
    
n.a. = not applicable    
ART = anti-retroviral therapy    
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Influenza specific CD4+ T cell-response 
The frequency of antigen-specific cells was quantified in ELISpot assays using a trivalent 
virosomal influenza vaccine (Inflexal®) as the source of antigen.  To define the cells contributing 
to the secretion of IFN-γ, aliquots of all samples were depleted of either CD4+ or CD8+ 
lymphocytes prior to performing ELISpot assays.  These control experiments confirmed that in 
vitro influenza vaccine almost exclusively triggers CD4+ and not CD8+ T cell-responses 
(Figure 1a).  To exclude the possibility that NK cells are contributing to the IFN-γ secretion we 
depleted samples from NK cells, which had no effect on the frequency of IFN-γ secreting cells 
(Figure 1b). 
Before vaccination the median frequency of IFN-γ secreting CD4+ T cells was comparable in HIV-
negative and HIV-infected individuals.  After vaccination the frequency significantly increased and 
reached comparable levels day 7 post-vaccination in both the HIV-negative and HIV-infected 
cohorts.  By contrast, 14 days after vaccination only in HIV-negative individuals the frequency of 
influenza-specific IFN-γ secreting CD4+ T cells remained increased.  By twenty-eight days after 
vaccination the frequency of IFN-γ secreting CD4+ T cells contracted to pre-vaccination levels in 
both HIV-negative and HIV-infected individuals (Figure 2). 
 
 
 
 
 
 
Figure 3.  Distribution of KIR genes among study participants.  KIR genotypes in HIV-negative study 
participants (Cohort 1 [n=23], and Cohort 2 [n=18]) and in HIV-infected study participants (n=21) were 
similar (p>0.2 for all comparisons). 
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Figure 4.  Relation of KIR genotype and vaccination-induced influenza-specific CD4+ T cell-response.  
(A) In HIV-negative individuals (Cohort 1 [n=23]) the presence of genes encoding for the activating receptors 
KIR2DS1 and KIR3DS1 was associated with a higher frequency of influenza-specific CD4+ T cells 7 days 
after vaccination.  No such association was detected for the activating receptors KIR2DS5, KIR2DS2 and 
KIR2DS3.  (B) In HIV-infected individuals (n=21) genes encoding for activating KIR did not relate to the 
expansion of influenza-specific CD4+ T cells.  (C) In a validation cohort (HIV-negative individuals; Cohort 2 
[n=18]) the association between the presence of the genes encoding for the activating receptors KIR2DS1 
and KIR3DS1 and the frequency of influenza-specific CD4+ T cells day 7 after vaccination was confirmed. 
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KIR / HLA genotypes 
KIR genotyping was performed sequentially, first in the exploratory study populations including 
HIV-negative and HIV-infected individuals, followed by the confirmatory cohort including HIV-
negative individuals only (Figure 3).  KIR gene distribution was similar in the three groups (p>0.2 
for all comparisons).  In line with the reported strong linkage disequilibrium between KIR2DS1 
and KIR3DS1, presence of these two genes was concordant in all individuals tested with the 
exception of one healthy donor in the validation cohort that carried KIR2DS1 but not 
KIR3DS1 [16].  For reasons of simplicity KIR2DS1 and KIR3DS1 are grouped together 
throughout the manuscript. 
 
 
 
 
Figure 5.  Relation of KIR/HLA compound genotype and vaccination-induced influenza-specific CD4+ T cell-
response.  The presence of compound KIR/HLA genotypes of known relevance was not associated with the 
frequency of influenza-specific CD4+ T cells 7 days after vaccination.  Shown is the mean effect (square) 
and 95% confidence interval (horizontal line) of the combined presence of KIR and cognate HLA ligand on 
ELISpot frequency as estimated by multivariable regression in the combined cohorts of HIV-negative study 
participants. 
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Associations between 'CD4+ T cell-response–KIR genotype' and 'CD4+ T cell-response 
–KIR/HLA compound genotype' 
KIR genes and the median frequencies of influenza-specific CD4+ T cells were related for each 
time-point in the exploratory cohorts (HIV-negative Cohort 1 and HIV-infected Cohort).  In HIV-
negative study participants, a genotype including KIR2DS1/KIR3DS1 was significantly associated 
with a higher count of influenza specific CD4+ T cells one week after vaccination (Figure 4A).  
None of the other KIR genes were associated with differing changes in the frequencies of vaccine 
specific CD4+ T cells (Figure 4A).  In HIV-infected individuals no link between a genotype 
including KIR2DS1/KIR3DS1 or any other KIR genes was detected for any time point 
(Figure 4B). 
To minimize the risk of describing chance associations we re-examined and confirmed the 
observed association between a genotype including KIR2DS1/KIR3DS1 and early post-vaccine 
frequencies of influenza-specific CD4+ T cells in an independent HIV-negative validation cohort 
(HIV-negative Cohort 2, n=18).  To avoid vaccine-type specific confounders a different type of 
vaccine (split vaccine) was used in the validation cohort (Figure 4C). 
Multivariable linear regression analysis was used to model the influenza-specific CD4+ T cell-
response over time.  This analysis confirmed a significant increase in IFN-γ producing CD4+ T 
cells that was confined to KIR2DS1/KIR3DS1 carrying individuals (Table 2).  Importantly, 
interaction analysis between HIV and KIR2DS1/KIR3DS1 carrier status resulted in a p-value of 
0.01, indicating that HIV significantly modulates the effect of KIR2DS1/KIR3DS1 on the influenza 
specific immune response (Table 2).  No significant differences or interactions were noted for any 
time point other than day 7 post-vaccination. 
In analogy, also KIR/HLA compound genotypes of established relevance were assessed 
(2DL1/C2, 2DL2/C1, 2DL3/C1, 3DL1/Bw4, 2DS1/C2, 2DS2/C1, 3DS1/Bw4) [7, 17, 18].  None of 
these compound genotypes had a measurable impact on the frequency of the vaccine-specific 
CD4+ T cell-response in the HIV-negative cohorts (Cohort 1 and 2 combined) (Figure 5).  In the 
HIV-infected cohort, the comparatively small patient population and skewing in HLA/KIR 
combinations (n≤2 for double-negative individuals in all 7 compound genotypes) precluded 
analysis of the effect of the compound HLA/KIR genotype. 
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Table 2. Statistical analyses. 
 
 
Median SFC/10^6 PBMC and interquartile ranges are given 
	
  
	
  
	
  
HIV 2DS1 - 64 (0-159) 85 (35-381) 0.14 70 (6-216) 0.68 57 (27-316) 0.59
} 0.32 } 0.8 } 0.81
HIV 2DS1+ 53 (0-340) 100 (30-380) 0.04 123 (25-496) 0.11 103 (23-595) 0.16
0.01 0.43 0.67
HD 2DS1- 35 (0-95) 65 (40-128) 0.25 95 (68-149) 0.01 50 (0-150) 0.17
} 0.002 } 0.1 } 0.56
HD 2DS1+ 29 (0-80) 169 (84-525) <0.001 112 (39-575) 0.001 0.07 0.07
}
P between 
groups
P vs 
Baseline
P vs 
Baseline4 Weeks
}
P between 
groups
Baseline 1 Week
}
P vs 
Baseline 2 Weeks
P between 
groups
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Discussion 
Innate immune responses are important for protecting the host early after infection, i.e. during the 
time when adaptive responses are evolving. 
Functional assays permitting to directly assess the features of innate immune-receptors 
belonging to the activating KIR-family remain elusive.  However, genetic association studies 
represent an important tool to gain insight into their biological roles.  Here we investigated in a 
human influenza-vaccination trial how KIR genotypes and KIR/HLA compound genotypes relate 
to the frequency of vaccine-induced CD4+ T cells.  The key findings of our study were that (i) a 
genotype including KIR2DS1/KIR3DS1 is associated with enhanced vaccine-induced CD4+ T 
cell-responses, and (ii) in HIV-infected individuals the relation between this KIR genotype and 
vaccine-induced CD4+ T cell-responses is dissociated.  No influence on vaccine-induced CD4+ T 
cell-responses by KIR/HLA compound genotypes was detected. 
In a number of immunogenetic association-studies combinations of KIR variants and HLA genes 
have been linked to the clinical course and/or outcome of human infections, including those with 
hepatitis C virus, HIV, human papillomavirus and cytomegalovirus [6, 8, 19-21].  Whether in these 
infections KIR impact on the course of disease directly or indirectly –e.g. by influencing adaptive 
immune responses– remains unknown.  Taking advantage of an experimental system that 
permits monitoring the expansion- and contraction-phase of an adaptive immune response, our 
data for the first time link KIR immunogenetics and the dynamics of adaptive immunity, 
suggesting an effect of KIR-triggered reactivities on the adaptive response in humans.  Thus, 
designing adjuvants able to mobilize KIR2DS1/KIR3DS1 expressing cells into the site of influenza 
vaccination may be an intriguing approach to enhance immunogenicity. 
In many of the study participants influenza vaccine-specific CD4+ T cells were detectable at low 
frequencies before vaccination already, reflecting prior contact with influenza antigen through 
vaccination or infection (shared antigens).  Thus –in the experimental setting applied here– no 
distinction between de novo induction of CD4+ T cell-responses and re-expansion of memory 
CD4+ T cells is made, and similar expansion was observed in both groups (data not shown).  It 
follows that the suggested KIR-dependent 'help' for CD4+ T cells likely applies to re-expansion of 
preformed memory and de novo priming alike, a finding that adds a novel facet to our 
understanding of the interaction between innate and adaptive immunity. 
In HIV infection NK cell-function is deregulated [15, 22].  Intriguingly, even under virological 
control and vis-à-vis relatively preserved CD4+ T cell-counts we here observed that cellular 
reactivities associated with KIR in HIV-negative individuals are not linked in the context of HIV-
infection. 
In summary, studying a model situation that allows associating innate immunogenetics with 
dynamic changes in adaptive cellular responses, our data differentially associate 
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KIR2DS1/KIR3DS1 and the adaptive CD4+ T cell response triggered by influenza vaccination in 
healthy vs. HIV-infected individuals.  From a clinical perspective it will be interesting to study 
whether the level of protection from influenza vaccine relates to the here-defined KIR genotype 
and, inversely, whether one could safely vaccinate genetically defined 'responders' with less 
antigen, which in turn might permit more efficient handling of limited resources. 
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Section 4: Mature dendritic cells trigger anti-proliferative activity in 
NK cells 
 
Stefanie Fritz, Bojana Durovic, Gabriela Zenhaeusern, Nikolai Hodel, Johannes Nemeth, Olivier 
Gasser, Christoph Hess. 
Abstract 
Interaction of dendritic cells (DCs) and natural killer (NK) cells has been demonstrated to impact 
the outcome of adaptive immune responses in various models. 
Here we show that mature monocyte-derived DCs (moDCs) selectively induce regulatory/anti-
proliferative activity in autologous NK cells.  Specifically, LPS-matured moDCs, but not immature 
moDCs, induced a population of IL-10 secreting NK cells.  Functionally, in the presence of 
autologous NK cells, allo T cell-proliferation induced by mature moDCs was significantly reduced.  
This NK cell-derived capacity to inhibit allo T cell-proliferation was transferable by supernatant 
from NK cells triggered by mature moDCs. 
Anti-proliferative NK cell-reactivity induced by mature moDCs may participate in the timely ending 
of DC-induced T cell expansion, a hypothesis that requires testing using in vivo models. 
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Introduction 
Immature dendritic cells (DCs) have high endocytic activity and low T cell activation potential, 
constantly sampling their environment for pathogens.  Upon receiving danger signals, DCs 
‘mature’ by increase MHC-expression and co-stimulatory molecules, now functioning as initiators 
of T cell immune responses and regulators of immune tolerance [1-3]. 
Natural killer (NK) cells represent a key effector-component of the innate immune system, able to 
produce cytokines and lyse cells without prior sensitization [4].  They compose approximately 10-
15% of circulating lymphocytes [5]. 
NK cells and DCs have been shown to interact at various stages during induction of an immune 
response.  In peripheral tissues, DC-derived soluble factors, as well as direct cell–cell 
interactions, can prime NK cells [6-8].  NK cells in turn can influence DC maturation and T cell 
polarization, as e.g. shown in a model where NK cell depleted mice infected with T. gondii 
showed impaired CD4+ T cell responses and enhanced susceptibility to infection [9].  In addition 
to DC-priming, NK cells can also kill autologous DCs both in non-lymphoid as well as in 
secondary lymphoid tissue, thereby ‘editing’ the nature of downstream adaptive (auto)immune 
responses [10, 11]. 
Although the biology of immature vs. mature DCs is fundamentally different, it remains unknown 
whether these DC maturation-subsets differentially trigger NK cells to secrete factors influencing 
T cell responsiveness.  To begin to address this important issue we here assessed the effect of 
immature vs. mature monocyte-derived DCs (moDCs) on the frequency of NK cells producing 
IFN-γ and IL-10, and on the capacity of NK cells and NK cell-derived soluble factors to influence 
moDC-mediated allo T cell-proliferation. 
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Materials and Methods 
Isolation, culture and generation of moDCs 
MoDCs were derived from moncytes isolated from fresh buffy coats.  Isolation of PBMC was 
performed by diluting a buffy coat 1/1 (v/v) with PBS (phosphate-buffered saline) prior to layering 
over Lymphoprep (Axis-Shield, Oslo, Norway).  PBMC were washed and cultured in R10 (RPMI 
1640 containing 10% heat inactivated Fetal Bovine Serum (FBS), 50 U/mL penicillin and 
50 µg/mL Streptomycin (all from GIBCO™, LuBioScience GmbH, Luzern, Switzerland) for 3h at 
37°C in 75mL flasks.  Aliquots of the cells were not added to the flasks, but frozen and stored at 
minus 80°C for subsequent isolation of NK cells.  After incubation of PBMC for 3h, non-adherent 
cells were removed by washing twice with R10.  The remaining cells were cultured in complete 
medium supplemented with 50 ng/mL GM-CSF and 50 ng/mL IL-4 (ImmunoTools).  On day 5, 
non-adherent immature moDCs were harvested, purified by Lymphoprep, plated in 6-well plates 
(1x10^5 cells/mL) and fractions were stimulated with LPS (10 ng/mL: LPS low; 100 ng/mL: 
LPS high) as indicated. 
 
Isolation of autologous NK cells 
On day 6, frozen PBMC were thawn and washed twice.  After an incubation period of 2h at 37°C, 
NK cells were isolated by negative isolation using magnetic-beads according to manufacturer`s 
protocol (Miltenyi Biotec, Bergisch-Gladbach, Germany).  Purity was assessed by flow cytometry 
(CD3neg, CD16+ and CD56+) and was always >98% (data not shown). 
 
FACScan analysis 
Antibodies recognizing CD3 (SK7), CD11c (S-HCL-3), CD14 (MOP9), CD16 (NKP15), CD56 
(B159), HLA-ABC (G46-2.6), HLA-DR (L243) and appropriate isotype controls all from BD 
Biosciences (BD Pharmingen, Allschwill, Switzerland) were used.  Data were acquired on a 
FACS Calibur flow cytometer and analyzed with the FlowJo 8.8.6 software (Tree Star, Inc., 
Ashland, Oregon, USA). 
 
Dual-color ELISpot assay 
ELISpot plates (MSIPS4510, Millipore AG, Volketswil, Switzerland) were coated with 2 µg/mL of 
anti- IFN γ mAb 1-D1K and anti-human interleukin-10 (IL-10) mAb (9D7) (Mabtech, Nacka Strand, 
Sweden) overnight.  In each well 5x10^4 paraformaldehyde-fixed moDCs as target cells and 
5x10^4 NK cells as effector cells in R10 were added in duplicates.  Plates were incubated for 
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16 h at 37°C with 5% CO2, washed with PBS and blocked with PBS 1% FBS.  After washing, 
plates were incubated with 100 µL anti-IFN-γ mAb (1:200) coupled with alkaline phosphatase (7-
B6-1-ALP, Mabtech) and biotinylated anti-human IL-10 mAB (1:2000) (12G8-Biotin) for 2 hours, 
followed by incubation with streptavidin-horseradish peroxidase (1:2000) (Mabtech) for 45min.  
Spots were developed with HistoMark® RED phosphatase system and HistoMark® TrueBlue 
peroxidase system (KPL, Gaithersburg, Maryland, USA) and counted with the ELISpot Reader 
System (CSR01, AID GmbH, Strassberg, Germany) using the ELISpot 3.5 software (AID GmbH). 
 
Proliferation assay 
To assess proliferation, moDCs and autologous NK cells were co-cultured in 96-well plates.  After 
overnight incubation, 5x10^4 allogeneic CD3+ T cells stained with CFSE were added 
(representing the effector/target ratio as optimized for the ELISpot assay).  Recombinant human 
IL-2 (Proleukin, Roche, Basel, Switzerland) was supplemented at a final concentration of 
250 U/mL and proliferation of allogeneic T cells was semi-quantified after 4 days by flow 
cytometry. 
 
Statistical analyses 
Normally distributed data were analyzed by Student`s t-test, non-normally distributed data by 
Mann-Whitney U test.  Paired analyses were performed as appropriate.  All tests were performed 
using Prism4 software (GraphPad Software, Inc. San Diego, California, USA). P values <0.05 
were considered statistically significant. 
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Results 
Mature moDCs trigger a subset of NK cells to secrete IL-10 
First we assessed secretion of IFN-γ and IL-10 by NK cells exposed to immature and mature 
autologous moDCs.  IFN-γ and IL-10 were chosen as prototypic indicators of pro- (IFN-γ) and 
anti-inflammatory/regulatory (IL-10) immune responses, respectively.  Specifically, we incubated 
NK cells with autologous immature moDCs and LPS-stimulated ('matured') moDCs overnight.  
LPS-induced maturation of moDCs was controlled for by assessing cell-surface expression of 
markers of mature moDCs, such as HLA class I, CD80 and CD86 (data not shown) [12, 13].  All 
experiments have been performed using moDCs from various donors.  Our focus was on 
studying the effect of direct moDC–NK cell interactions under non-changing conditions and in 
absence of DC-derived factors.  Therefore, prior to co-culture experiments, moDCs were mildly 
fixed with paraformaldehyde [14].  NK cells induced to secrete IFN-γ and/or IL-10 through contact 
with moDCs were enumerated using dual color ELISpot technology. 
In these experiments only minimal induction of IFN-γ was observed either after incubation of 
NK cells with immature or mature moDCs.  Intriguingly however, mature –i.e. LPS-activated 
moDCs– but not immature moDCs induced a population of NK cells to secrete IL-10 (Fig. 1).  
These data indicated that a subset of NK cells could be triggered to secrete the regulatory/anti-
inflammatory cytokine IL-10 when interacting with LPS-matured autologous moDCs. 
 
 
Figure 1.  NK cells are capable to recognize LPS-activated DCs.  NK cells were mixed with autologous 
moDCs (stimulated [DCs plus LPS] or non-stimulated [immature DC; iDC]), which were fixed using a mild 
paraformaldehyde (PAF) (0,2%) solution to abolish cytokine production.  Frequencies of IFN-γ and IL-10 
secreting NK cells were measured by dual color ELISpot assay.  NK cells did not produce IFN-γ vis-à-vis 
autologous iDCs, but maturation of moDCs induced IL-10 secretion in a subset of NK cells.  Results 
represent mean ± SD of four experiments.  **p<0.005 
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Figure 2. LPS matured moDCs induce autologous NK cells to secrete anti-proliferative factors.  MoDCs 
were either left untreated (immature moDCs), or matured with LPS (LPS-matured moDCs).  Cytokine 
production of moDCs was abolished using mild paraformaldehyde-fixation.  Immature and LPS-matured 
MoDC-subsets were then cultured with autologous NK cells overnight.  Subsequently, allogeneic T cells 
(plus IL-2) were added, and proliferation of allogeneic T cells was measured after 4 days of co-culture.  
(A) Allogeneic T cell-proliferation was more efficiently induced by LPS-matured than by immature moDCs 
(upper panel).  Allogeneic T cell-proliferation –as induced by LPS-matured moDCs– was suppressed when 
LPS-matured moDCs were incubated with autologous NK cells prior to the addition of allo T cells (upper vs. 
middle panel).  This inhibitory effect was transferable using conditioned culture medium from LPS-matured 
moDCs incubated with autologous NK cells (lower panel).  (B) MoDCs matured with either a low or a high 
concentration of LPS, but not immature moDCs, induced inhibitory NK cell-reactivity.  However, moDCs 
matured with a low LPS-concentration induced inhibitory NK cell-reactivity less consistently than moDCs 
matured with a higher concentration of LPS (middle vs. right panel) (n=17).  (C) Supernatant from co-culture 
experiments of moDCs and autologous NK cells (n=17) consistently reproduced the NK cell-mediated effect 
on allo T cell-proliferation.  n.s. = not significant; ** p<0.005; *** p<0.001. 
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Inhibition of allogeneic T cell-proliferation 
To examine the functional impact of moDC-induced regulatory NK cell activity –as exemplified by 
the secretion of IL-10– we next assessed their effect on allo T cell-proliferation.  To that end, 
NK cells and mildly fixed autologous moDCs –either immature or LPS-matured– were co-cultured 
for 24h prior to adding allogeneic T cells (moDC:NK cell:allo T cell ratio = 1:1:1 ; established as 
optimal ratio in exploratory experiments).  Proliferation of T cells was then assessed after 4 days 
of allo-stimulation. 
Using this experimental system, immature moDCs induced proliferation in ~10% of allogeneic 
T cells, LPS-matured moDCs in ~30% of allogeneic T cells (Fig. 2A, upper row).  Co-incubating 
NK cells and immature moDCs had no effect on allo T cell-proliferation.  By contrast, co-
incubation of LPS-matured moDCs with NK cells reduced allo T cell-proliferation by 
approximately half (reduction from ~30% to ~20% against ~10% baseline allo-proliferation) 
(Fig. 2A, middle row).  Reduced allo-proliferation was not rescued by adding IL-2 (data not 
shown).  To define whether cell contact is required to inhibit the observed allo T cell-proliferation, 
the anti-proliferative capacity of supernatant from co-cultures of fixed immature and LPS-matured 
moDCs with NK cells was assessed.  While supernatant from NK cells co-cultured with immature 
moDCs had no impact on allo T cell-proliferation, allo-proliferation was again reduced by 
approximately half using supernatant from NK cells co-cultured with LPS-matured moDCs 
(Fig. 2A, lower row). 
Of note, while recombinant IL-10 at high concentrations was also able to suppress allo T cell-
proliferation, no relevant impact was observed when adding IL-10 at concentrations detected in 
the supernatant from NK cells activated by LPS-matured moDCs (data not shown).  Blocking of 
IL-10, using blocking antibodies, also had no effect (data not shown). 
Results from all 17 allo T cell-proliferation experiments are summarized in Figure 2B.  Overall, 
LPS-matured moDCs (either LPS low or LPS high) induced stronger allo T cell-proliferation than 
immature moDCs (p<0.001).  Co-culturing autologous NK cells with immature moDCs had no 
significant effect on their capacity to induce allo-proliferation (Fig. 2B, left panel).  By contrast, 
allo-proliferation was significantly reduced when adding autologous NK cells to LPS-matured 
moDCs (either LPS low or LPS high) (Fig. 2B, middle and right panel).  Both magnitude and 
consistency of the effect of LPS-matured moDCs on NK cell-mediated inhibition of allo T cell-
proliferation were dependent on the dose of LPS used to mature moDCs (magnitude: median 
inhibition mediated by NK cells incubated with (i) immature, (ii) LPS low and (iii) LPS high stimulated 
moDCs; -1%, 15% and 18%; consistency: effect observed in 8/17, 13/17 and 16/17 experiments, 
respectively).  Comparing the effect on allo T cell-proliferation of ‘NK cell–allo T cell co-incubation’ 
vs. ‘NK cell-conditioned supernatant’ across all 17 experiments confirmed that the observed effect 
was dependent on one or several NK cell-derived soluble factor(s) (Fig. 2C). 
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Discussion 
To function efficiently, T cell immunity depends on the induction of an appropriately sized and 
polarized effector population during a defined window of time.  While many of the signals/factors 
defining T cell polarization have been well defined, less is known on mechanisms regulating the 
duration during which T cell immunity can and should be induced [15, 16].  Regulatory/anti-
proliferative reactivity of NK cells induced by mature moDCs –as observed in the current study– 
may reflect a mechanism limiting in time the period during which T cell immunity can be triggered.  
In the model studied here –where moDCs were mildly fixed using paraformaldehyde– induction of 
immunosuppressive NK cell reactivity by moDCs strictly depended on cell–cell contact.  This 
system permitted us to study the effect on NK cells of stable, non-changing moDC populations.  
Our ‘reductionist’ approach permitted us to define the fact that anti-proliferative properties are 
selectively induced in NK cells upon interaction with LPS-matured moDCs.  This approach is, 
however, limited by the fact that in vivo, DC subsets interact with NK cells in a dynamic setting, in 
changing environments, and are responding to these interactions by secreting cytokines, changes 
in cell-surface phenotype, etc.  The here presented data thus can only be viewed as a prototypic 
NK cell reactivity inducible by mature moDCs.  Testing its immunological in vivo relevance now 
requires models that take into account the dynamics of an immune response. 
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Future perspectives: 
The immune response induced by influenza-vaccination (Part I) 
Virosome-based vaccines (VBV) –as used in the vaccination studies described in this thesis– 
promote antigen presentation both via MHC class I as well as MHC class II [1,2].  In general, 
administration of VBV leads to a good antibody response as it mimics natural viral infections.  
Why some individuals do not generate protecting antibodies after VBV remains unknown.  
As an immediate follow-up to the studies presented in this thesis-work it will now be interesting to 
use hemagglutinin-derived peptide loaded tetramers to further characterize the influenza-specific 
population induced by vaccination and to use proliferation/re-expansion assays to begin to 
understand the potential of the influenza VBV to induce distinct memory T cell populations [3]. 
 
Establishing cell lines expressing KIR2DS1 or KIR3DS1 
The best-described model of NK cells fighting viral infections is the murine cytomegalovirus 
(MCMV) model.  In humans, functional evidence on the protective role of KIR remains sparse.  
Alter et al. performed one of the first in vitro functional NK cell studies.  In their work they were 
able to provide functional evidence with regards to the protective role of KIR3DS1+ and HLA-
Bw4-80I in progressing AIDS. Another recently published study providing functional KIR data 
demonstrated that KIR2DS1 recognizes the C2 molecule with a 50% lower avidity than its 
counterpart KIR2DL1 [4].  Little is known regarding clonal expansion of NK cells bearing 
activating receptors in human infection.  Alter et al. reported a specific expansion of KIR3DS1+ 
and KIR3DL1+ NK cells during acute HIV-1 infection in the presence of HLA-Bw4-80I [5].  This 
finding is in line with a dramatic expansion of a Ly49H-bearing NK cells in the model of MCMV 
[6]. 
Aiming to functionally assess the observed association between KIR 2DS1 and 3DS1 genotype 
and outcome after influenza vaccination we decided to establish single KIR expressing cell lines.  
To that end we chose NK-92 and YT cells to perform stable transfections.  NK-92 is a human 
natural killer lymphoma cell line, which is devoid of KIR and grows in the presence of IL-2.  YT is 
human T/NK cell leukemia cell line which is also devoid of KIR and furthermore of CD3, and has 
been reported to be easier to be transfected than NK-92.  Once these cell lines are stably 
transfected with KIR2DS1 and KIR3DS1, respectively, the following experiments will be 
performed:  Transfected cells expressing KIR 2DS1 and 3DS1, respectively, will be incubated 
with either the virosome-based vaccine or hemagglutinin and neuraminidase.  Additionally, target 
cells, which are positive for different genotypes, for example C2 molecule or HLA-Bw4-80I, will be 
added for co-incubation.  Binding will be assessed by flow cytometry and confocal microscopy. 
Since NK cells express a number of activating/inhibiting receptors, this reductionist approach may 
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shed light on the function of these specific KIR.  We also aim to functionally characterize KIR–KIR 
ligand interactions using cell lysis assays and measurements of induced cytokine production. 
New insights into the immune response after virosome-based vaccines (Part II) 
Characterizing the subsets that are induced after vaccination and that appear in the peripheral 
blood circulation in fingolimod-treated individuals will require experiments similar as those 
outlined above (“The immune response induced by influenza-vaccination (Part I)”).  Specifically in 
fingolimod-treated individuals it will be interesting to determine the mechanism(s) allowing 
peptide-triggered T cells to egress from the lymph nodes despite the inhibiting effect of 
fingolimod.  To that end chemotaxis assays using S1P as well as other T cell chemoattractants 
will be performed.  Another unresolved issue is whether the quality of the antibody response in 
fingolimod-treated individuals is also unchanged.  Preliminary experiments analyzing the avidity 
of influenza-specific antibodies indicate that no correlation exists between the quantity and quality 
(i.e. avidity) in fingolimod-treated individuals and healthy controls (D. Eichin et al., unpublished 
observations). 
Towards defining the soluble, NK cell-derived T cell-inhibitory molecules 
In a series of experiments we have already started to investigate what soluble factors might 
confer the observed NK cell-derived T cell inhibitory effect (‘blocking signal’ in the summary 
sketch below; Figure 1).  We initially focused on the two anti-inflammatory cytokines IL-10 and 
TGF-β1.  While indeed allo-proliferation of T cells could be reduced in the presence of IL-10 as 
well as in the presence of TGF-β1, cytokine concentrations released by mature moDC-triggered 
NK cells were much lower than the ones required to inhibit allo T cell proliferation.  Neutralizing 
IL-10 and TGF-β1 using neutralizing antibodies in our experimental system also had no impact.  
The search for the inhibitory factor(s) induced in NK cells by mature moDC is ongoing.  Towards 
defining the molecular interaction that is inducing the observed inhibitory activity in NK cells, 
blocking experiments (e.g. blocking HLA – KIR interactions) will be performed. 
 
Figure 1 Model of a potential interaction between NK cells and mature moDC. 
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